1. Home
  2. UVV vs EYPT Comparison

UVV vs EYPT Comparison

Compare UVV & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

HOLD

Current Price

$53.24

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$12.39

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVV
EYPT
Founded
1886
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
1994
2005

Fundamental Metrics

Financial Performance
Metric
UVV
EYPT
Price
$53.24
$12.39
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$31.80
AVG Volume (30 Days)
217.0K
850.5K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
6.25%
N/A
EPS Growth
N/A
N/A
EPS
1.30
N/A
Revenue
$2,885,078,000.00
$7,539,000.00
Revenue This Year
$0.67
N/A
Revenue Next Year
$0.10
$3,115.57
P/E Ratio
$40.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$49.19
$8.37
52 Week High
$61.67
$19.11

Technical Indicators

Market Signals
Indicator
UVV
EYPT
Relative Strength Index (RSI) 47.94 40.98
Support Level $51.47 $11.55
Resistance Level $54.23 $14.73
Average True Range (ATR) 1.57 0.77
MACD -0.14 -0.02
Stochastic Oscillator 65.45 37.33

Price Performance

Historical Comparison
UVV
EYPT

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: